Home › Funds › Atom Investors LP › DNTH
Atom Investors LP position in DNTH
DIANTHUS THERAPEUTICS INC COM · Health Care
Atom Investors LP reported holding 37,228 shares of DNTH (DIANTHUS THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$3.6M, representing 0.32% of its reported portfolio and ranking #44 among its reported holdings. Atom Investors LP has disclosed DNTH holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Atom Investors LP's DNTH position evolved
Atom Investors LP first disclosed a stake in DNTH in Q3 2025 at 61,038 shares (US$2.4M). The position peaked in Q1 2026 at 107,753 shares, worth US$9.0M. Across 4 filings, Atom Investors LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 37,228 shares valued at US$3.6M — a reduction of -70,525 shares quarter over quarter.. Notable position changes include a 198% increase in Q4 2025 (shares rose 104% over the following quarter), a 41% trim in Q1 2026 (shares rose 16% over the following quarter), a 65% trim in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 61.04K | $2.40M | New |
| Q4 2025 | 181.86K | $7.49M | Add |
| Q1 2026 | 107.75K | $9.04M | Reduce |
| Q2 2026 | 37.23K | $3.63M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNTH and 13F data
DNTH (DIANTHUS THERAPEUTICS INC COM) is a Health Care company. 73 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNTH
- Fairmount Funds Management LLC 2.54M sh · $247.33M · Q2 2026
- Avidity Partners Management LP 2.10M sh · $205.12M · Q2 2026
- Octagon Capital Advisors LP 1.84M sh · $179.53M · Q2 2026
- TCG Crossover Management, LLC 1.68M sh · $163.44M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 1.30M sh · $126.97M · Q2 2026
- Venrock Adviser, LLC 1.18M sh · $115.03M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.13M sh · $109.70M · Q2 2026
- BAKER BROS. ADVISORS LP 852.16K sh · $83.07M · Q2 2026
- Logos Global Management LP 800.00K sh · $77.98M · Q2 2026
- Cormorant Asset Management, LP 750.00K sh · $73.11M · Q2 2026
- BRAIDWELL LP 594.56K sh · $57.96M · Q2 2026
- MPM BioImpact LLC 420.00K sh · $40.94M · Q2 2026
More on Atom Investors LP
FAQ
How long has Atom Investors LP held DNTH?
Atom Investors LP has disclosed DNTH holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Atom Investors LP's current position in DNTH?
As of Q2 2026, Atom Investors LP holds 37.23K shares of DNTH (DIANTHUS THERAPEUTICS INC COM), valued at $3.63M, representing 0.32% of its reported portfolio and ranking #44.
Has Atom Investors LP been buying or selling DNTH?
In the latest 13F filing (Q2 2026), Atom Investors LP reduced its position in DNTH. The position peaked in Q1 2026 at 107.75K shares.
Which other funds hold DNTH?
Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.